Theragnostics 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
1 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ATT001 / Ariceum Therap
CITADEL-123, NCT06650605: Phase 1 Open-label Study of 123I-ATT001 in Subjects with Relapsed Glioblastoma

Recruiting
1
67
Europe
123I-ATT001
Theragnostics Ltd
Glioma Glioblastoma Multiforme
12/26
04/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ATT001 / Ariceum Therap
CITADEL-123, NCT06650605: Phase 1 Open-label Study of 123I-ATT001 in Subjects with Relapsed Glioblastoma

Recruiting
1
67
Europe
123I-ATT001
Theragnostics Ltd
Glioma Glioblastoma Multiforme
12/26
04/27

Download Options